vs
Lakeside Holding Ltd（LSH）与SUTRO BIOPHARMA, INC.（STRO）财务数据对比。点击上方公司名可切换其他公司
SUTRO BIOPHARMA, INC.的季度营收约是Lakeside Holding Ltd的1.7倍（$11.6M vs $7.0M），Lakeside Holding Ltd同比增速更快（95.0% vs -21.4%）
莱克赛德出版社是位于美国芝加哥的出版品牌，由RR唐纳利公司运营。该社除了出版高品质书籍外，还承印邮购目录、电话号码簿、百科全书与广告宣传品，最为人熟知的是为芝加哥卡克斯顿俱乐部出版的高端版本，以及经典重印丛书《莱克赛德经典》。
Sutro Biopharma是一家上市生物科技公司，总部位于加州南旧金山，专注于临床阶段药物的研发、开发与生产。公司依托自主专有的无细胞蛋白质合成平台，结合蛋白质工程与理性设计技术开发肿瘤治疗药物。公司2003年成立时名为Fundamental Applied Biology，2009年改用现名。
LSH vs STRO — 直观对比
营收规模更大
STRO
是对方的1.7倍
$7.0M
营收增速更快
LSH
高出116.4%
-21.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $7.0M | $11.6M |
| 净利润 | $-1.6M | — |
| 毛利率 | 27.2% | — |
| 营业利润率 | -21.3% | — |
| 净利率 | -22.6% | — |
| 营收同比 | 95.0% | -21.4% |
| 净利润同比 | 18.7% | 35.4% |
| 每股收益（稀释后） | $-0.08 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LSHSTRO
| Q4 25 | $7.0M | $11.6M | ||
| Q3 25 | $6.1M | $9.7M | ||
| Q2 25 | $6.3M | $63.7M | ||
| Q1 25 | $3.8M | $17.4M | ||
| Q4 24 | $3.6M | $14.8M | ||
| Q3 24 | $4.1M | $8.5M | ||
| Q2 24 | — | $25.7M | ||
| Q1 24 | — | $13.0M |
净利润LSHSTRO
| Q4 25 | $-1.6M | — | ||
| Q3 25 | $-1.4M | $-56.9M | ||
| Q2 25 | $-893.1K | $-11.5M | ||
| Q1 25 | $-1.1M | $-76.0M | ||
| Q4 24 | $-1.9M | $-72.4M | ||
| Q3 24 | $-1.3M | $-48.8M | ||
| Q2 24 | — | $-48.0M | ||
| Q1 24 | — | $-58.2M |
毛利率LSHSTRO
| Q4 25 | 27.2% | — | ||
| Q3 25 | 18.2% | — | ||
| Q2 25 | 26.7% | — | ||
| Q1 25 | 18.8% | — | ||
| Q4 24 | -1.2% | — | ||
| Q3 24 | 12.8% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
营业利润率LSHSTRO
| Q4 25 | -21.3% | — | ||
| Q3 25 | -20.8% | -499.9% | ||
| Q2 25 | -8.9% | -5.2% | ||
| Q1 25 | -28.2% | -393.8% | ||
| Q4 24 | -55.6% | -440.7% | ||
| Q3 24 | -32.5% | -797.2% | ||
| Q2 24 | — | -189.4% | ||
| Q1 24 | — | -435.0% |
净利率LSHSTRO
| Q4 25 | -22.6% | — | ||
| Q3 25 | -22.2% | -586.6% | ||
| Q2 25 | -14.2% | -18.0% | ||
| Q1 25 | -28.2% | -436.6% | ||
| Q4 24 | -54.1% | -489.2% | ||
| Q3 24 | -32.7% | -572.6% | ||
| Q2 24 | — | -186.8% | ||
| Q1 24 | — | -447.5% |
每股收益（稀释后）LSHSTRO
| Q4 25 | $-0.08 | — | ||
| Q3 25 | $-0.09 | $-0.67 | ||
| Q2 25 | $-0.11 | $-0.14 | ||
| Q1 25 | $-0.14 | $-0.91 | ||
| Q4 24 | $-0.26 | $-27.63 | ||
| Q3 24 | $-0.18 | $-0.59 | ||
| Q2 24 | — | $-0.59 | ||
| Q1 24 | — | $-0.59 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.6M | $141.4M |
| 总债务越低越好 | $2.4M | — |
| 股东权益账面价值 | $12.2M | $-132.5M |
| 总资产 | $24.3M | $173.8M |
| 负债/权益比越低杠杆越低 | 0.20× | — |
8季度趋势，按日历期对齐
现金及短期投资LSHSTRO
| Q4 25 | $1.6M | $141.4M | ||
| Q3 25 | $4.5M | $167.6M | ||
| Q2 25 | $5.0M | $205.1M | ||
| Q1 25 | $1.5M | $249.0M | ||
| Q4 24 | $1.1M | $316.9M | ||
| Q3 24 | $2.7M | $388.3M | ||
| Q2 24 | — | $375.6M | ||
| Q1 24 | — | $267.6M |
总债务LSHSTRO
| Q4 25 | $2.4M | — | ||
| Q3 25 | $2.4M | — | ||
| Q2 25 | $1.4M | — | ||
| Q1 25 | $774.2K | — | ||
| Q4 24 | $784.8K | — | ||
| Q3 24 | $589.9K | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益LSHSTRO
| Q4 25 | $12.2M | $-132.5M | ||
| Q3 25 | $7.0M | $-87.3M | ||
| Q2 25 | $2.8M | $-32.1M | ||
| Q1 25 | $749.8K | $-25.8M | ||
| Q4 24 | $1.6M | $44.6M | ||
| Q3 24 | $3.6M | $111.2M | ||
| Q2 24 | — | $152.2M | ||
| Q1 24 | — | $98.0M |
总资产LSHSTRO
| Q4 25 | $24.3M | $173.8M | ||
| Q3 25 | $18.6M | $209.7M | ||
| Q2 25 | $14.4M | $262.4M | ||
| Q1 25 | $9.9M | $321.4M | ||
| Q4 24 | $9.8M | $387.2M | ||
| Q3 24 | $10.8M | $451.8M | ||
| Q2 24 | — | $489.0M | ||
| Q1 24 | — | $403.4M |
负债/权益比LSHSTRO
| Q4 25 | 0.20× | — | ||
| Q3 25 | 0.35× | — | ||
| Q2 25 | 0.48× | — | ||
| Q1 25 | 1.03× | — | ||
| Q4 24 | 0.48× | — | ||
| Q3 24 | 0.16× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-453.5K | $-177.2M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流LSHSTRO
| Q4 25 | $-453.5K | $-177.2M | ||
| Q3 25 | $-4.0M | $-38.2M | ||
| Q2 25 | $-483.7K | $-44.7M | ||
| Q1 25 | $-238.3K | $-67.9M | ||
| Q4 24 | $-530.2K | $-71.7M | ||
| Q3 24 | $-1.4M | $-64.5M | ||
| Q2 24 | — | $9.5M | ||
| Q1 24 | — | $-64.7M |
自由现金流LSHSTRO
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-497.4K | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-560.5K | — | ||
| Q3 24 | $-1.4M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
自由现金流率LSHSTRO
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -7.9% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -15.6% | — | ||
| Q3 24 | -34.5% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
资本支出强度LSHSTRO
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.2% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.8% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LSH
| Transferred Over Time | $4.6M | 65% |
| Distribution Of Pharmaceutical Products | $2.4M | 35% |
STRO
暂无分部数据
